Q2 EPS Estimates for Ovid Therapeutics Cut by William Blair

Ovid Therapeutics Inc. (NASDAQ:OVID) – Stock analysts at William Blair dropped their Q2 2025 earnings estimates for shares of Ovid Therapeutics in a note issued to investors on Wednesday, March 12th. William Blair analyst S. Schram now anticipates that the company will post earnings of ($0.15) per share for the quarter, down from their prior forecast of ($0.14). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.74) EPS.

OVID has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a report on Wednesday, January 29th. Finally, Wedbush restated an “outperform” rating and set a $3.00 price target (down previously from $4.00) on shares of Ovid Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Ovid Therapeutics presently has an average rating of “Buy” and an average price target of $3.20.

Ovid Therapeutics Stock Down 1.4 %

NASDAQ OVID opened at $0.43 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. The company’s 50 day simple moving average is $0.65 and its 200 day simple moving average is $0.95. Ovid Therapeutics has a 12 month low of $0.42 and a 12 month high of $3.45. The company has a market capitalization of $30.81 million, a P/E ratio of -0.92 and a beta of 0.29.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its position in Ovid Therapeutics by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock worth $35,000 after acquiring an additional 17,172 shares in the last quarter. XTX Topco Ltd grew its position in Ovid Therapeutics by 46.2% in the third quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock worth $45,000 after acquiring an additional 12,076 shares in the last quarter. Bank of America Corp DE grew its position in Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after acquiring an additional 18,841 shares in the last quarter. FMR LLC grew its position in Ovid Therapeutics by 1,907.4% in the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after acquiring an additional 47,723 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in Ovid Therapeutics in the fourth quarter worth approximately $65,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.